Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo

Combination therapy concurrently targeting PD1 and CTLA4 immune checkpoints leads to remarkable anti-tumor effects. While both PD1 and CTLA4 dampen the T cell activation, the in vivo effects of these drugs in humans remain to be clearly defined. In order to better understand biologic effects of ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunol
Main Authors: Das, Rituparna, Verma, Rakesh, Sznol, Mario, Boddupalli, Chandra Sekhar, Gettinger, Scott N., Kluger, Harriet, Callahan, Margaret, Wolchok, Jedd D, Halaban, Ruth, Dhodapkar, Madhav V., Dhodapkar, Kavita M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4380504/
https://ncbi.nlm.nih.gov/pubmed/25539810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1401686
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados